Resistant hypertension: patient characteristics, risk factors, co-morbidities and outcomes. - Wikidata - awgldk - TriplyDB

Resistant hypertension: patient characteristics, risk factors, co-morbidities and outcomes.

Resistant hypertension: patient characteristics, risk factors, co-morbidities and outcomes.

http://www.wikidata.org/entity/Q38132337

about

Association of Matrix Metalloproteinase-9 Gene -1562C/T Polymorphism with Essential Hypertension: A Systematic Review and Meta-Analysis Article Clinical Features of Obstructive Sleep Apnea That Determine Its High Prevalence in Resistant Hypertension.Evaluation of the relationship between T663A polymorphism in the alpha-epithelial sodium channel gene and essential hypertension.Resistant hypertension in type 2 diabetes: prevalence and patients characteristics.Asymptomatic hyperuricemia is a strong risk factor for resistant hypertension in elderly subjects from general population.Interventional therapy for hypertension: Back on track again?Device-Based Therapy for Drug-Resistant Hypertension: An Update.Should All Patients with Resistant Hypertension Receive Spironolactone?Pharmacotherapy of 'treatment resistant' type 2 diabetes.Clinical characteristics, target organ damage and associate risk factors of resistant hypertension determined by ambulatory blood pressure monitoring in patients aged ≥ 80 years.

P2860

Q26770159-B79FE917-64E0-44DB-9A31-07637DCCE506 Q35971053-9F5ADCCA-AE1F-429B-876F-AE6EC90C98F7 Q36184961-B7CDF112-FB87-449A-8676-6487D95C13AB Q36247763-EC73C8E1-5E71-4411-8D39-62414432E007 Q37674063-6C1330A2-B771-4AB4-AEA7-B4E7AFB20C79 Q38860497-C19EE682-2A50-4987-91B8-F4043315051A Q38893138-8A91C3AD-D804-4CDD-8CAC-F5AAA8942990 Q38992649-78BAB1B8-D947-4B6F-8406-0ED8F9423E44 Q39170345-15999BC9-0AE4-49E8-8F5A-055FF56DA850 Q42209115-F5C34B76-121F-4698-A979-FD9F127F4A75

P2860

Resistant hypertension: patient characteristics, risk factors, co-morbidities and outcomes.

http://www.wikidata.org/entity/Q38132337

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Resistant hypertension: patien ...... , co-morbidities and outcomes.

@en

type

label

Resistant hypertension: patien ...... , co-morbidities and outcomes.

@en

prefLabel

Resistant hypertension: patien ...... , co-morbidities and outcomes.

@en

P1433

Q38132337-824C6511-84A1-4D93-AD71-C53123C37BD2

P1476

Q38132337-0E3A777C-CBBB-4E69-9533-06861C65E6C0

P2093

Q38132337-28382FAE-E69A-44EB-869E-6255807875EF

P2860

Q38132337-0641A05A-45D6-4562-9765-A70679093ADD

Q38132337-077BA222-5FA7-46C9-8D24-156C237AC1A3

Q38132337-0B759537-1415-4DB6-BAD6-C631E1C632EB

Q38132337-289C9A35-CBB6-4FAE-8D6E-73AABB4243F7

Q38132337-2C63E367-F4C9-4F3B-A7FB-1F8D07438C97

Q38132337-4AC02134-0C7A-4F6E-A2D2-E36B38475AB5

Q38132337-534F9497-56EA-4F25-A614-F8BCBB9E00EC

Q38132337-55BDF880-81DC-44E5-99EF-E3F747514620

Q38132337-5AB819B9-5D77-4387-9DC6-DAE31488ED62

Q38132337-6DF024E5-8534-4401-A2FA-C2A5E02FBBC4

P2888

Q38132337-64D13ACE-FCA8-4DE9-AC5C-BD1E3361523E

P304

Q38132337-C0F568DA-4F4C-4545-B327-461FF845E1B5

P31

Q38132337-A757ABA9-F4D5-4732-80A8-1A24F6032D76

P356

Q38132337-ECA2FC21-ECDD-4BD2-96A2-D6FF4E18C5ED

P433

Q38132337-6C81A8E7-7FCC-4F2B-B6BF-65C67DC1FCCE

P478

Q38132337-DEFB03C8-355E-4526-80A9-FED04B157EF8

P50

Q38132337-7DF2636F-14F6-4331-9508-F2E6FFD2A73E

P577

Q38132337-0E47FE60-694F-4B63-B774-BB2C736FE4DC

P6179

Q38132337-09913FAB-8E25-4B46-B0E4-4F3D11A9B326

P698

Q38132337-EF29A3E9-C4DB-4EB7-A301-AE989F85378E

P921

Q38132337-E1BDB7A9-6D07-4506-89BE-48BF23CE3914

P356

P1433

Journal of Human Hypertension

P1476

Resistant hypertension: patien ...... s, co-morbidities and outcomes

@en

P2093

A de la Sierra

http://www.w3.org/2001/XMLSchema#string

P2860

Human adipocytes secrete mineralocorticoid-releasing factors.

Is resistant hypertension really resistant?

Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.

Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months.

Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial.

Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008

Incidence and prognosis of resistant hypertension in hypertensive patients.

Refractory hypertension: definition, prevalence, and patient characteristics.

Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism

P2888

P304

213-217

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/JHH.2013.77

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-08-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1009662059

http://www.w3.org/2001/XMLSchema#string

P698

23985879

http://www.w3.org/2001/XMLSchema#string

P921

arterial hypertension